Blackstone, Intellia, Cellex to launch company addressing limitations of cell therapies
Blackstone Life Sciences has committed $250 million toward the launch of a new autologous and allogeneic universal chimeric antigen receptor T-cell therapy company. Also taking part in the launch are Intellia Therapeutics and Cellex Cell Professionals, the parent company of GEMoaB, a clinical-stage cell therapy company. Read More
NanoString releases nCounter stem cell characterization panel
NanoString Technologies has unveiled its nCounter stem cell characterization panel for the analysis and optimization of stem cell lines for humans and mice. Read More
PerkinElmer agrees to acquire Sirion Biotech
PerkinElmer has entered into an agreement to acquire Sirion Biotech, a provider of viral vector-based technology for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021. Read More
Benchling launches digital solution for RNA therapeutic discovery, development
Benchling has launched a digital solution for scientists to design, analyze, and develop complex RNA therapeutics in a single research and development platform. Read More
Nuevocor secures $24M for cardiac gene therapies
Nuevocor has completed a $24 million financing round to accelerate the preclinical development of its lead program, an adeno-associated virus-based gene therapy for patients with cardiomyopathy due to mutations in the lamin A/C (LMNA) gene. Read More
Personalized cell therapies offer hope for some of the toughest cancers
Complete with a long-term vision of developing a pipeline of oncology therapies that modulate the functional immune system, Sotio of the Czech Republic is breaking into the world of autologous immuno-oncology therapies. The company's goal is to eventually become a prominent European pharmaceutical firm, according to Radek Špíšek, PhD, CEO and founding scientist of Sotio, who spoke with ScienceBoard.net in a recent interview. Read More
Danaher to acquire Aldevron in deal valued at $9.6B
Danaher announced it has signed a deal to buy DNA and messenger RNA manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as a standalone company in Danaher's Life Sciences business segment and is expected to boost Danaher's activities in genomic medicine. Read More
Kite and Shoreline partner on allogeneic cell therapies
Biopharmaceutical company Kite announced a partnership with Shoreline Biosciences to develop novel cell therapies across a variety of cancer targets. Read More
Dendreon to offer end-to-end cell therapy manufacturing
California-based Dendreon Pharmaceuticals announced that it will offer end-to-end manufacturing for complex cell therapies. Read More
Kytopen granted SBIR for nonviral NK cell gene editing platform
Kytopen has been awarded a Small Business Innovation Research (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases to demonstrate that its nonviral delivery platform can enable natural killer (NK) cell gene editing at research and manufacturing scales. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter